MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and anti-retroviral activity of MK-8510 monotherapy in anti-retroviral-naïve HIV-1 infected participants.

Timeline

Start

2023-04-17

Primary completion

2024-02-14

Completion

2024-02-14

Outcome

Outcome not reported

Stopped (Business): “Business Reasons”

Drugs

Indications